Cover Image

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review

Atopic dermatitis (AD) is a common skin condition characterized by inflammation that presents with erythematous and pruritic skin. Its chronic relapse-remitting nature has a significant impact on the quality of life, and often requires ongoing management. Given the limited treatments available for A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuliya Lytvyn (Author), Asfandyar Mufti (Author), Abrahim Abduelmula (Author), Muskaan Sachdeva (Author), Khalad Maliyar (Author), Jorge R. Georgakopoulos (Author), Jensen Yeung (Author)
Format:	Book
Published:	MDPI AG, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
by: Yuliya Lytvyn, et al.
Published: (2022)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
by: Hagino T, et al.
Published: (2023)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
by: Asfandyar Mufti, MD, et al.
Published: (2021)

COVID-19 and wound care: A Canadian perspective
by: Asfandyar Mufti, MD, et al.
Published: (2020)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
by: S. K. Zyryanov, et al.
Published: (2023)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
by: Teppei Hagino, et al.
Published: (2024)

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
by: Ana Batalla, et al.
Published: (2023)

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
by: Shawn G. Kwatra, et al.
Published: (2024)

Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab
by: Yan Yang, et al.
Published: (2023)

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
by: April W. Armstrong, et al.
Published: (2024)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
by: Yuliya Lytvyn, et al.
Published: (2023)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
by: S. Martínez-Fernández, et al.
Published: (2023)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
by: Siddhartha Sood, HBSc, et al.
Published: (2023)

Dermatology: how to manage atopic dermatitis in patients with skin of colour
by: Muskaan Sachdeva, et al.
Published: (2022)

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
by: Luigi Gargiulo, et al.
Published: (2024)

Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis
by: Mahreen Ameen, et al.
Published: (2024)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literatureCapsule Summary
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
by: Emily Seale, MPH, et al.
Published: (2023)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
by: Jannett Nguyen, MD, et al.
Published: (2021)

Real-World Experience of Upadacitinib Dosing Reduction in Patients With Moderate Atopic Dermatitis: A Case Series Study in Taiwan
by: Yang-Yi Chen, et al.
Published: (2024)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023)

Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023)

Use of sulfasalazine for psoriasis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023)

Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata,
by: Guilherme Muzy
Published: (2024)

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
by: Ibba L, et al.
Published: (2024)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
by: Norito Katoh, et al.
Published: (2023)

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients
by: Francesco Piscazzi, et al.
Published: (2023)

Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report
by: Ting Pan, et al.
Published: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib
by: Takeshi Koga, et al.
Published: (2024)

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
by: Adrien Mareschal, et al.
Published: (2020)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
by: Ling Li, et al.
Published: (2023)